Correlation of HER-2/neu Expression with Histopathological and Prognostic Parameters in Colorectal Cancers

Yıl 2020, Cilt: 7 Sayı: 3, 145 - 149, 29.12.2020

Serkan Yaşar Çelik , Leyla Tekin

https://doi.org/10.47572/muskutd.767857

Öz

Colorectal cancer is the most common type of gastrointestinal cancers. It is the second most common cancer in women and the third in men and it is the third leading cause of cancer-related death. Although prognosis is associated with many clinical and pathological parameters, the most important factor is TNM stage. However, despite the same pathological stage, there are also differences between prognoses in different patients. This situation reveals the need for new prognostic and predictive factors except the TNM stage. HER-2/neu, also known as C-erbB-2, is a gene that encodes a transmembrane protein with tyrosine kinase activity and closely related to the epidermal growth factor. Overexpression of HER-2/neu has been detected in many epithelial malignancies such as lung, prostate, bladder, pancreas and breast. The aim of this study is to determine the expression of HER-2/neu oncogene in colorectal cancers by immunohistochemical methods, to evaluate the relationship between overexpression and various prognostic factors. In our study, we selected resection materials of 111 patients diagnosed as colorectal cancer in our hospital between 2013 and 2020, and performed immunohistochemical staining automatically with anti-C-erbB-2 antibody (Leica) in Leica Bond-Max device. Overexpression of HER-2/neu was found to be significantly associated with pathological stage, tumor differantion, lymphovascular invasion, perineural invasion, radial surgical margin positivity, lymph node involvement and presence of distant metastases. These results suggest that the detection of HER-2/neu expression in patients with colorectal cancer may be helpful in predicting the prognosis of the disease and determining the treatment protocols.

Anahtar Kelimeler

Colorectal Cancer, HER-2/neu, Prognosis

Kolorektal Kanserlerde HER-2/neu Ekspresyonunun Histopatolojik ve Prognostik Parametrelerle Korelasyonu

Öz

Kolorektal kanser gastrointestinal kanserlerin en sık görülen tipidir, kadınlarda ikinci, erkeklerde üçüncü en yaygın görülen kanserdir ve kansere bağlı ölüm nedenleri arasında 3. sıradadır. Prognoz birçok klinik ve patolojik parametre ile ilişkili olsa da en önemli faktör TNM sınıflamasına göre olan evresidir. Ancak aynı patolojik evrede olmasına rağmen prognozlar arasında farklılıklar da bulunmaktadır. Bu durum TNM evresi dışında yeni prognostik ve prediktif faktörlere olan ihtiyacı ortaya koymaktadır. C-erbB-2 olarak da bilinen, tirozin kinaz aktivitesi ile bir transmembran proteini kodlayan gen olan HER-2/neu, epidermal büyüme faktörü ile biyolojik olarak yakından ilişkili bir protoonkogendir. HER2/neu’nun aşırı ekspresyonu akciğer, prostat, mesane, pankreas ve meme gibi birçok epitelyal malignitelerde tespit edilmiştir. Bu çalışmanın amacı; kolorektal kanserlerde HER-2/neu onkogeni ekspresyonunu immunohistokimyasal yöntemlerle belirlemek, aşırı ekspresyonu ile çeşitli prognostik faktörler arasındaki ilişkiyi incelemektir. Çalışmamızda 2013-2020 tarihleri arasında hastanemizde kolorektal kanser tanısı alan 111 olguya ait rezeksiyon materyallerinden seçilen tümörlü bloklardan Leica Bond-Max cihazında, anti-C-erbB-2 antikoru(Leica) kullanılarak otomatik sistemle immunohistokimyasal boyama yapıldı. HER-2/neu’nun aşırı ekspresyonu patolojik evre, tümör diferansiasyonu, lenfovasküler invazyon, perinöral invazyon, çevre(radial) cerrahi sınır pozitifliği, lenf nodu tutulumu ve uzak metastaz varlığı ile anlamlı derecede ilişkili olduğu saptandı. Bu sonuçlar, kolorektal kanserli hastalarda HER-2/neu ekspresyonunun tespitinin, hastalığın prognozunu öngörmede ve tedavi protokollerinin belirlenmesinde yol gösterici olabileceğini düşündürmektedir.

Anahtar Kelimeler

HER-2/neu, Kolorektal Kanser, Prognoz

Kaynakça

• 1. WHO Classification of Tumours Editorial Board. Digestive system tumours, 5th Edition. 158-191. Lyon(France): International Agency for Research on Cancer, 2019.
• 2. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival and risk factors. Gastroenterol Rev. 2019;14(2):89-103.
• 3. Rosai J.Rosai and Ackerman’s Surgical Pathology. 10th ed. St Louis, MO:St Louis Mosby, 2011:731-803.
• 4. Li Q, Wang D, Li J and Chen P. Clinicopathological and prognostik significance of HER-2/neu and VEGF expression in colon carcinomas. BMC Cancer. 2011;11:277.
• 5. Albayrak A, Gürsan N, Gündoğdu C. Kolorektal kanserlerde c-erbB-2 ve p53 ekspresyonunun prognostik önemi. JCEI. 2014;5(1):80-5.
• 6. Yıldırım S, Dandin O, Durmus M ve ark. C-erb-B2(Her2/neu) Expression Rate And its Association with Clinicopathologic Parameters in Gastric Cancer. UHOD. 2012;22(3):156-62.
• 7. Valorta E, Martino C, Sartore-Bianchi A ve ark. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Modern Pathol. 2015; 28: 1481-91.
• 8. Farzand S, Siddique T, Saba K, Bukhari MH. Frequency of HER2/neu overexpression in adenocarcinoma of the gastrointestinal system. World J Gastroenterol. 2014;20(19):5889-96.
• 9. Yao YF, Du CZ, Chen N, Chen P, Gu J. Expression of HER-2 in rectal cancers Treated With preoperative Raditherapy:a potential Biomarker Predictive of Metastasis. Dis Colon Rectum. 2014;57:602-7.
• 10. Gao FJ, Chen JY, Wu HY ve ark. Lgr5 over-expression is positively related to the tumor progression and HER2 expression in stage pTNM IV colorectal cancer. Int J Clin Exp Pathol. 2014;7(4):1572-9.
• 11. Drecoll E, Nitsche U, Bauer K ve ark. Expression analysis of heat shock protein 90(HSP90) and Her2 in colon carcinoma. Int J Colorectal Dis. 2014;29:663-71.
• 12. Madani SH, Sadeghi E, Rezaee A ve ark. Survey of HER2-neu Expression in Colonic Adenocarcinoma in the West of Iran. Asian Pac J Cancer Prev. 2015; 16(17):7671-4.
• 13. Sayadnejad N, Firouzjahi A, Shafaee S ve ark. Immunohistochemical Study of HER2/neu Expression in colorectal Cancer and its Relation to other Clinicopathological Criteria and Prognostic Factors. Int J Cancer Manag. 2017;10(5):e5700.
• 14. Priyanka G, Joseph LD, Barathi G, Kumbhat M. HER 2/neu as a theranostic marker in colorectal carcinoma and its relationship with histopathological correlates-A pilot study. Indian J Pathol Oncol. 2017;4(3):446-9.
• 15. Sun SJ, Lin Q, Sun Q et al. High HER-2 protein levels correlate with clinicopathological features in colorectal cancer. J Can Res Ther. 2016;12(1):323-33.
• 16. Li JL, Lin SH, Chen HQ et al. Clinical significance of HER2 and EGFR expression in colorectal cancer patients with ovarian metastasis. BMC Clinical Pathol. 2019;19:3.